| Recruiting | A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participant NSCLC, Stage IB-IIIA, Lung Cancer, Adjuvant | Phase 3 | 2025-12-22 |
| Enrolling By Invitation | Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy Advanced/Metastatic Cancer | Phase 2 / Phase 3 | 2024-10-01 |
| Active Not Recruiting | REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation | Phase 3 | 2023-12-18 |
| Recruiting | A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Rece Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations | Phase 2 | 2023-07-31 |
| Active Not Recruiting | Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer | Phase 2 | 2023-07-13 |
| Recruiting | Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement | Phase 2 | 2023-07-05 |
| Terminated | A Study of TAS3351 in NSCLC Patients With EGFRmt Non-Small Cell Lung Cancer | Phase 1 | 2023-05-25 |
| Active Not Recruiting | A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone Relapsed/Refractory Peripheral T-cell Lymphoma | Phase 1 | 2023-02-22 |
| Recruiting | Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | 2022-12-23 |
| Recruiting | Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | 2021-12-15 |
| Terminated | Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer, KRAS Gene Mutation | Phase 1 | 2021-09-20 |
| Terminated | A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer Solid Tumor, Glioblastoma, Non-small Cell Lung Cancer | Phase 1 | 2021-09-16 |
| Terminated | TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating Mutations | Phase 1 | 2021-03-31 |
| Active Not Recruiting | Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AM Acute Myeloid Leukemia | Phase 1 / Phase 2 | 2021-02-09 |
| Terminated | Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma Advanced and Metastatic Urothelial Cancer | Phase 2 | 2021-01-07 |
| Terminated | Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholan Advanced Cholangiocarcinoma, FGFR2 Gene Rearrangements | Phase 3 | 2021-01-06 |
| Completed | Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Can Refractory Metastatic Colorectal Cancer | Phase 3 | 2020-11-25 |
| Terminated | A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer Advanced or Metastatic Solid Tumors | Phase 1 | 2020-10-15 |
| Terminated | Futibatinib in Patients With Specific FGFR Aberrations Advanced or Metastatic Solid Tumor, Advanced or Metastatic Gastric or Gastroesophageal Cancer, Myeloid or Lymphoid Neoplasms (MLN) | Phase 2 | 2020-08-05 |
| Recruiting | A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm | Phase 2 / Phase 3 | 2020-05-21 |
| Terminated | A Study of TAS1440 With ATRA in Subjects With r/r AML Acute Myeloid Leukemia | Phase 1 | 2020-03-15 |
| Terminated | A Study of TAS-120 in Patients With Metastatic Breast Cancer Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification | Phase 2 | 2020-01-28 |
| Enrolling By Invitation | A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes | Phase 2 | 2019-09-30 |
| Terminated | Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53 Solid Tumor | Phase 1 | 2019-07-11 |
| Completed | Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS Myelodysplastic Syndromes | Phase 1 / Phase 2 | 2018-07-27 |
| Completed | Study of ASTX029 in Subjects With Advanced Solid Tumors Solid Tumor, Adult | Phase 1 / Phase 2 | 2018-05-07 |
| Terminated | A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities Advanced Solid Tumors With HER2 Abnormalities, Advanced Solid Tumors With HER3 Abnormalities | Phase 1 | 2018-04-06 |
| Completed | A Study of TAS-116 in Patients With Solid Tumors Advanced Solid Tumors | Phase 1 | 2017-07-10 |
| Terminated | The CHOICE Registry Metastatic Colorectal Cancer | — | 2017-06-30 |
| Terminated | A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma Multiple Myeloma, NonHodgkin Lymphoma | Phase 1 | 2017-03-01 |
| Completed | A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1 Advanced or Metastatic Non-small Cell Lung Cancer | Phase 2 | 2016-08-29 |
| Completed | A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC Refractory Metastatic Colorectal Cancer | Phase 2 | 2016-08-29 |
| Completed | Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer Metastatic Castration Resistant Prostate Cancer | Phase 1 | 2016-03-01 |
| Completed | Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer Refractory Metastatic Gastric Cancer | Phase 3 | 2016-02-24 |
| Active Not Recruiting | Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas Solid Tumors, Lymphoma | Phase 1 / Phase 2 | 2015-07-14 |
| Completed | A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment Advanced Solid Tumors | Phase 1 | 2015-01-01 |
| Completed | A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment Advanced Solid Tumors | Phase 1 | 2015-01-01 |
| Terminated | An Investigation of TAS-119 Monotherapy Advanced Solid Tumors | Phase 1 | 2014-09-01 |
| Terminated | Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors | Phase 1 | 2014-08-01 |
| Completed | A Study of TAS-120 in Patients With Advanced Solid Tumors Cholangiocarcinoma, Urothelial Cancer, Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors | Phase 1 / Phase 2 | 2014-07-21 |
| Completed | Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2014-02-01 |
| Completed | A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors. Advanced Gastrointestinal Tumors | Phase 1 | 2013-09-01 |
| Terminated | A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Plat Small Cell Lung Cancer (SCLC) | Phase 2 | 2013-07-01 |
| Completed | Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FT Advanced Solid Tumors (Excluding Breast Cancer) | Phase 1 | 2013-07-01 |
| Completed | Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors Advanced Solid Tumors (Excluding Breast Cancer) | Phase 1 | 2013-06-01 |
| Completed | Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone Advanced Solid Tumors | Phase 1 | 2013-05-01 |
| Completed | A Trial of TAS-114 in Combination With S-1 Advanced Solid Tumors | Phase 1 | 2013-03-01 |
| Completed | A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Neoplasms | Phase 1 | 2012-11-01 |
| Completed | Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies Colorectal Cancer | Phase 3 | 2012-06-17 |
| Terminated | Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction | Phase 3 | 2011-04-14 |
| Withdrawn | A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular C Advanced Hepatocellular Carcinoma | Phase 2 | 2008-10-01 |
| Terminated | Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sora Hepatocellular Carcinoma | Phase 2 | 2008-08-01 |
| Terminated | Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Ja Advanced Hepatocellular Carcinoma | Phase 2 | 2008-04-24 |
| Completed | A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Tumors | Phase 1 | 2006-09-01 |
| Completed | Evaluating Patients With Impaired Hepatic Function Impaired Hepatic Function | Phase 1 | 2006-02-01 |
| Completed | Evaluating Patients With Varying Degrees of Renal Function Renal Impairment | Phase 1 | 2006-02-01 |
| Completed | Phase 2 Study of S-1 in Advanced or Metastatic Pancreatic Cancer Locally Advanced or Metastatic Pancreatic Cancer | Phase 2 | 2006-01-09 |
| Completed | Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer Metastatic Pancreatic Cancer | Phase 2 | 2005-06-01 |
| Completed | A Safety and Efficacy Study in Patients With Gastric Cancer Gastric Cancer | Phase 3 | 2005-05-01 |
| Completed | Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer Advanced Non-Small Cell Lung Cancer | Phase 2 | 2005-02-01 |
| Completed | Phase 2 Study of S-1 in Combination With Cisplatin as 1st Line Therapy in Advanced Non-Small Cell Lung Cancer Advanced Non-Small Cell Lung Cancer | Phase 2 | 2005-02-01 |
| Completed | Phase 1/2 Study of S-1 and Cisplatin in Advanced Gastric Cancer Gastric Cancer | Phase 1 / Phase 2 | 2003-10-01 |
| Approved For Marketing | Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer Colorectal Cancer Metastatic | — | — |
| Approved For Marketing | Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangeme Advanced Cholangiocarcinoma | — | — |